Navigation Links
Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million
Date:11/20/2013

DURHAM, N.C., Nov. 20, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that on November 4, 2013, the Company increased the size of its previously announced Series E financing by $17.5 million, bringing the total amount of committed funds from $42.5 million to $60 million.

In August 2013, Argos announced the closing of a $42.5 million Series E financing.  The additional $17.5 million investment represents additional commitments from current Argos investors and one new investor. The funds from the Series E financing will be used to support the Company's ongoing ADAPT pivotal Phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC). 

"This funding further strengthens our ability to advance our ADAPT clinical trial.  In addition, the company is now better positioned to consider and pursue a range of options to support our global manufacturing and commercialization plans based on the potential of our Arcelis™ technology platform," said Jeff Abbey, Argos' president and chief executive officer.

About the Arcelis™ Technology Platform
Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Arcelis process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform.  Argos' most advanced product candidate, AGS-003, has initiated a pivotal Phase 3 study for the treatment of mRCC, and the Company recently completed enrollment of its Phase 2b study of AGS-004 for the treatment of HIV. For more information about Argos Therapeutics, visit www.argostherapeutics.com.


'/>"/>
SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
3. Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
4. Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... Tenn. and BENTON, Ky. , Aug. 2, 2017   ... member to its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections ... a UV disinfection robot that uses UVC light energy to kill deadly pathogens such as ... ... Tru-D in ...
(Date:7/31/2017)... July 31, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has ... Michigan by Crain,s Detroit Business . ... public companies by three-year revenue growth. This year,s edition measures ... To view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... an incredible triumph," said Phil Hagerman , CEO and ...
(Date:7/28/2017)... , July 28, 2017 EnvoyHealth, a Diplomat ... pilot a program for CleverCap LITE, a technology designed ... strives to deliver innovative health technology solutions and services ... CleverCap LITE offers medication ... high-tech bottle cover: ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... ... Of Spiritual Duty”: a revelation in an era defined by intentional confusion. “Call Of ... the streets of North Visalia, California, Carlos Lizarde quickly became familiar with life’s hardships ... life, he noticed immediately that opportunities and blessings began to shift in his favor. ...
(Date:8/21/2017)... Louis, MO (PRWEB) , ... August 22, 2017 , ... ... career fairs to help healthcare employers connect with physicians and advanced practitioners like ... virtual career fairs in August through November of this year. The online ...
(Date:8/21/2017)... Garden City, NY (PRWEB) , ... August 22, ... ... (NAPW) honors Judith I. Stevens as a 2017-2018 inductee into ... distinction for leadership in entrepreneurship. NAPW is the nation’s leading networking organization exclusively ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... FCPX LUT ... Editors can quickly and easily add washed color grades to footage. A LUT ... LUT changes every pixel’s color to the corresponding color indicated by the table. This ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior assisted living homes ... , Guests will be able to vote for their favorite Chef among the ... Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice Tea ...
Breaking Medicine News(10 mins):